article thumbnail

Q&A: Why drafting new rules on ultra-processed foods is so hard

STAT

Whole grain cereal and breads also qualify for the label, as do yogurts and some other dairy desserts. Processed meats, as their name would suggest, also belong in this category. But ultra-processed foods are not all the same.

article thumbnail

Zydus receives USFDA approval to conduct Phase II(b) clinical trial for Usnoflast, a novel oral NLRP3 inflammasome inhibitor in patients with ALS

Express Pharma

This study consists of a 36-week treatment phase, followed by a 16-week open-label extension. This study will enrol 210 ALS patients and study doses of 50 mg and 75 mg Usnoflast versus placebo.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

FDA AdCom votes in favour of Lundbeck’s/Otsuka’s Rexulti in AAD

Pharmaceutical Technology

The current unmet need, the benefit of treatment with Rexulti, and a reasonable safety profile persuaded Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School, to give a positive vote. Rexulti is an atypical antipsychotic.

article thumbnail

Over-the-Counter Choices Pharmacist Role and Resources

FADIC

OTC drugs come in various forms, including tablets, capsules, creams, and liquids, and are generally labeled with clear instructions on proper usage and dosage. The FDA’s website provides a wealth of information on OTC drugs, including product labels, warnings, and recalls.

article thumbnail

Almirall/Lilly lebrikizumab offers potential long-term management of atopic dermatitis

pharmaphorum

He has been a research fellow at Harvard Medical School, Boston, the University of California, San Francisco, and University Spital Zürich, Switzerland, where his research focused on atopic dermatitis and the complexity of the skin barrier.

article thumbnail

Biogen and Eisai’s Alzheimer’s drug secures support in closely watched AdCom

Pharmaceutical Technology

The evidence for clinical benefit was “very clear”, said Dr. Merit Cudkowicz, Julieanne Dorn professor of neurology at Harvard University’s Medical School. Robert Alexander, research professor at the University of Arizona’s College of Medicine, who voted in favour of Leqembi at the 9 June meeting.

article thumbnail

Pharmacovigilance deep dive: risk minimisation measures

European Pharmaceutical Review

She also has been conducting fundamental research as an academic in several universities, with her last academic position held at Harvard Medical School. She holds a MSc in Public Health and a PhD in Biophysics and Molecular Biology. About the author. Hannah Balfour is the Science Writer for European Pharmaceutical Review. References.